Lumasiran Sodium Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 94.5 mg/0.5 mL
Reference Brands: Oxlumo (USA)
Category:
Orphan Drugs
Lumasiran Sodium is available in Injection
and strengths such as 94.5 mg/0.5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lumasiran Sodium is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lumasiran Sodium can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) therapeutic developed to treat primary hyperoxaluria type 1 (PH1) by directly addressing the metabolic pathway responsible for excessive oxalate production. It works through RNA interference by specifically targeting the hydroxyacid oxidase 1 (HAO1) messenger RNA in hepatocytes. This action leads to a reduction in the production of the glycolate oxidase (GO) enzyme in the liver.
Lower levels of glycolate oxidase result in decreased conversion of glycolate to glyoxylate, which is a key precursor in the formation of oxalate. By reducing the availability of glyoxylate, lumasiran significantly lowers urinary and plasma oxalate levels, thereby addressing the underlying cause of disease manifestations in patients with PH1, including kidney stone formation and progressive renal damage.
Importantly, the mechanism of action of lumasiran is independent of the specific AGXT gene mutation responsible for PH1. Because glycolate oxidase functions upstream of the deficient alanine:glyoxylate aminotransferase (AGT) enzyme, lumasiran is effective across different genetic variants of the disease. This targeted, gene-silencing approach represents a disease-modifying strategy and a major advancement in the management of primary hyperoxaluria type 1.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing